XBIO
Xenetic Biosciences, Inc.
NASDAQ · Healthcare · Biotechnology · US
$4.67
+0.86%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 3.3M | 3.0M | 2.5M | 2.5M | 1.7M |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | 3.3M | 3.0M | 2.5M | 2.5M | 1.7M |
| Operating Expenses | |||||
| R&D Expense | 2.7M | 3.1M | 3.3M | 3.5M | 4.8M |
| SG&A Expense | 3.2M | 2.7M | 3.4M | 3.6M | 3.7M |
| General & Admin Expense | 3.2M | 2.7M | 3.4M | 3.6M | 3.7M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 5.9M | 5.8M | 6.7M | 7.1M | 8.4M |
| Cost and Expenses | 5.9M | 5.8M | 6.7M | 7.1M | 8.4M |
| Operating Income (EBIT) | (2.6M) | (2.8M) | (4.2M) | (4.5M) | (6.7M) |
| Non-Operating | |||||
| Interest Income | 162.4K | 148.0K | 249.9K | 355.8K | 167.2K |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | 162.4K | 148.0K | 249.9K | 355.8K | 167.2K |
| Other Non-Op Income/Expense | 166.5K | 153.7K | 244.2K | 381.1K | 165.6K |
| Non-Operating Income (excl Interest) | (166.5K) | (153.7K) | (244.2K) | (381.1K) | (165.6K) |
| EBT (Pre-Tax Income) | (2.5M) | (2.7M) | (4.0M) | (4.1M) | (6.6M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (2.5M) | (2.7M) | (4.0M) | (4.1M) | (6.6M) |
| Earnings from Cont. Ops | (2.5M) | (2.7M) | (4.0M) | (4.1M) | (6.6M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (2.5M) | (2.7M) | (4.0M) | (4.1M) | (6.6M) |
| Per Share | |||||
| Basic EPS | ($1.19) | ($1.58) | ($2.57) | ($2.71) | ($4.49) |
| Diluted EPS | ($1.19) | ($1.58) | ($2.57) | ($2.71) | ($4.49) |
| Revenue Per Share | $1.42 | $1.75 | $1.62 | $1.66 | $1.20 |
| Shares | |||||
| Basic Shares Outstanding | 2.3M | 1.7M | 1.5M | 1.5M | 1.4M |
| Diluted Shares Outstanding | 2.3M | 1.7M | 1.5M | 1.5M | 1.4M |
| Profitability Metrics | |||||
| EBITDA | (2.5M) | (2.7M) | (3.8M) | (4.1M) | (6.5M) |
| D&A | — | — | 153.3K | — | 27.0K |
| EBIT | (2.5M) | (2.7M) | (4.0M) | (4.1M) | (6.6M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026